BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kronbichler A, Windpessl M, Pieringer H, Jayne DRW. Rituximab for immunologic renal disease: What the nephrologist needs to know. Autoimmun Rev 2017;16:633-43. [PMID: 28414152 DOI: 10.1016/j.autrev.2017.04.007] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 6.2] [Reference Citation Analysis]
Number Citing Articles
1 Kronbichler A, Gauckler P, Bruchfeld A. Rituximab in minimal change disease and focal segmental glomerulosclerosis. Nephrol Dial Transplant 2021;36:983-5. [PMID: 31580445 DOI: 10.1093/ndt/gfz205] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
2 Kronbichler A. Biological Agents and Therapeutic Plasma Exchange: Can They Coexist in the Future?: Invited Editorial. Ther Apher Dial 2017;21:553-5. [DOI: 10.1111/1744-9987.12639] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
3 Kronbichler A, Brezina B, Gauckler P, Quintana LF, Jayne DRW. Refractory lupus nephritis: When, why and how to treat. Autoimmun Rev 2019;18:510-8. [PMID: 30844548 DOI: 10.1016/j.autrev.2019.03.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 6.3] [Reference Citation Analysis]
4 Odler B, Windpessl M, Krall M, Steiner M, Riedl R, Hebesberger C, Ursli M, Zitt E, Lhotta K, Antlanger M, Cejka D, Gauckler P, Wiesholzer M, Saemann M, Rosenkranz AR, Eller K, Kronbichler A. The Risk of Severe Infections Following Rituximab Administration in Patients With Autoimmune Kidney Diseases: Austrian ABCDE Registry Analysis. Front Immunol 2021;12:760708. [PMID: 34777374 DOI: 10.3389/fimmu.2021.760708] [Reference Citation Analysis]
5 Liu D, Zhou Z, Wang M, Nie S, Li J, Hu B, He W, Wang G, Ai J. Extended infusion of rituximab combined with steroids is effective in inducing remission and reducing relapse in adult minimal change disease. BMC Nephrol 2021;22:242. [PMID: 34210283 DOI: 10.1186/s12882-021-02437-4] [Reference Citation Analysis]
6 Bersano A, Kraemer M, Burlina A, Mancuso M, Finsterer J, Sacco S, Salvarani C, Caputi L, Chabriat H, Oberstein SL, Federico A, Lasserve ET, Hunt D, Dichgans M, Arnold M, Debette S, Markus HS. Heritable and non-heritable uncommon causes of stroke. J Neurol 2021;268:2780-807. [PMID: 32318851 DOI: 10.1007/s00415-020-09836-x] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Arrestier R, Satie AP, Zhang SY, Plaisier E, Isnard-Bagnis C, Gatault P, Raimbourg Q, Buob D, Vocila F, Heng AE, Francois H, Moktefi A, Canaud G, Matignon M, Dejucq-Rainsford N, Brocheriou I, Sahali D, Audard V. Minimal change nephrotic syndrome in patients infected with human immunodeficiency virus: a retrospective study of 8 cases. BMC Nephrol 2018;19:331. [PMID: 30458703 DOI: 10.1186/s12882-018-1132-x] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
8 Lee JM, Kronbichler A, Shin JI, Oh J. Current understandings in treating children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 2021;36:747-61. [PMID: 32086590 DOI: 10.1007/s00467-020-04476-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Santos JE, Fiel D, Santos R, Vicente R, Aguiar R, Santos I, Amoedo M, Pires C. Rituximab use in adult glomerulopathies and its rationale. J Bras Nefrol 2020;42:77-93. [PMID: 31904761 DOI: 10.1590/2175-8239-JBN-2018-0254] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
10 Selmi C. Autoimmunity in 2017. Clinic Rev Allerg Immunol 2018;55:239-53. [DOI: 10.1007/s12016-018-8699-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Topakian R, Zimprich F, Iglseder S, Embacher N, Guger M, Stieglbauer K, Langenscheidt D, Rath J, Quasthoff S, Simschitz P, Wanschitz J, Windisch D, Müller P, Oel D, Schustereder G, Einsiedler S, Eggers C, Löscher W. High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria. J Neurol 2019;266:699-706. [DOI: 10.1007/s00415-019-09191-6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 8.7] [Reference Citation Analysis]
12 Alamilla-Sanchez ME, Alcala-Salgado MA, Alonso-Bello CD, Fonseca-Gonzalez GT. Mechanism of Action and Efficacy of Immunosupressors in Lupus Nephritis. Int J Nephrol Renovasc Dis 2021;14:441-58. [PMID: 34924767 DOI: 10.2147/IJNRD.S335371] [Reference Citation Analysis]
13 Salvarani C, Brown RD Jr, Muratore F, Christianson TJH, Galli E, Pipitone N, Cassone G, Huston J III, Giannini C, Warrington K, Hunder GG. Rituximab therapy for primary central nervous system vasculitis: A 6 patient experience and review of the literature. Autoimmun Rev 2019;18:399-405. [PMID: 30743080 DOI: 10.1016/j.autrev.2018.12.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
14 Santos JE, Fiel D, Santos R, Vicente R, Aguiar R, Santos I, Amoedo M, Pires C. Rituximab use in adult glomerulopathies and its rationale. J Bras Nefrol. 2020;42:77-93. [PMID: 31904761 DOI: 10.1590/2175-8239-] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Girimaji N, Bharati J, Nada R, Rathi M, Kohli HS, Ramachandran R. Rituximab in treatment of collapsing FSGS-A case series. Nephrology (Carlton) 2021;26:134-41. [PMID: 32662534 DOI: 10.1111/nep.13757] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Kronbichler A, Lee KH, Denicolò S, Choi D, Lee H, Ahn D, Kim KH, Lee JH, Kim H, Hwang M, Jung SW, Lee C, Lee H, Sung H, Lee D, Hwang J, Kim S, Hwang I, Kim DY, Kim HJ, Cho G, Cho Y, Kim D, Choi M, Park J, Park J, Tizaoui K, Li H, Smith L, Koyanagi A, Jacob L, Gauckler P, Shin JI. Immunopathogenesis of ANCA-Associated Vasculitis. Int J Mol Sci 2020;21:E7319. [PMID: 33023023 DOI: 10.3390/ijms21197319] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
17 Crayne CB, Eloseily E, Mannion ML, Azerf SP, Weiser P, Beukelman T, Stoll ML, Feig DI, Prescott Atkinson T, Cron RQ. Rituximab treatment for chronic steroid-dependent Henoch-Schonlein purpura: 8 cases and a review of the literature. Pediatr Rheumatol Online J 2018;16:71. [PMID: 30428889 DOI: 10.1186/s12969-018-0285-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
18 Gauckler P, Shin JI, Alberici F, Audard V, Bruchfeld A, Busch M, Cheung CK, Crnogorac M, Delbarba E, Eller K, Faguer S, Galesic K, Griffin S, van den Hoogen MWF, Hrušková Z, Jeyabalan A, Karras A, King C, Kohli HS, Mayer G, Maas R, Muto M, Moiseev S, Odler B, Pepper RJ, Quintana LF, Radhakrishnan J, Ramachandran R, Salama AD, Schönermarck U, Segelmark M, Smith L, Tesař V, Wetzels J, Willcocks L, Windpessl M, Zand L, Zonozi R, Kronbichler A; RITERM study group. Rituximab in Membranous Nephropathy. Kidney Int Rep 2021;6:881-93. [PMID: 33912740 DOI: 10.1016/j.ekir.2020.12.035] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
19 Tullus K, Webb H, Bagga A. Management of steroid-resistant nephrotic syndrome in children and adolescents. Lancet Child Adolesc Health 2018;2:880-90. [PMID: 30342869 DOI: 10.1016/S2352-4642(18)30283-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 12] [Article Influence: 6.3] [Reference Citation Analysis]
20 Colucci M, Carsetti R, Serafinelli J, Rocca S, Massella L, Gargiulo A, Lo Russo A, Capponi C, Cotugno N, Porzio O, Onetti Muda A, Palma P, Emma F, Vivarelli M. Prolonged Impairment of Immunological Memory After Anti-CD20 Treatment in Pediatric Idiopathic Nephrotic Syndrome. Front Immunol 2019;10:1653. [PMID: 31379849 DOI: 10.3389/fimmu.2019.01653] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
21 Park JG, Na M, Kim MG, Park SH, Lee HJ, Kim DK, Kwak C, Kim YS, Chang S, Moon KC, Lee DS, Han SS. Immune cell composition in normal human kidneys. Sci Rep 2020;10:15678. [PMID: 32973321 DOI: 10.1038/s41598-020-72821-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
22 Windpessl M, Burgstaller S, Kronbichler A, Pieringer H, Kalev O, Karrer A, Wallner M, Thaler J. Progressive Multifocal Leukoencephalopathy Following Combined Rituximab-Based Immune-Chemotherapy for Post-transplant Lymphoproliferative Disorder in a Renal Transplant Recipient: A Case Report. Transplant Proc. 2018;50:881-883. [PMID: 29661457 DOI: 10.1016/j.transproceed.2018.01.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
23 Salvarani C, Brown RD Jr, Christianson TJH, Huston J 3rd, Giannini C, Hunder GG. Long-term remission, relapses and maintenance therapy in adult primary central nervous system vasculitis: A single-center 35-year experience. Autoimmun Rev 2020;19:102497. [PMID: 32062032 DOI: 10.1016/j.autrev.2020.102497] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
24 Anders HJ, Wilkens L, Schraml B, Marschner J. One concept does not fit all: the immune system in different forms of acute kidney injury. Nephrol Dial Transplant 2021;36:29-38. [PMID: 32337558 DOI: 10.1093/ndt/gfaa056] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Wijetilleka S, Mukhtyar C, Jayne D, Ala A, Bright P, Chinoy H, Harper L, Kazmi M, Kiani-Alikhan S, Li C, Misbah S, Oni L, Price-Kuehne F, Salama A, Workman S, Wrench D, Karim MY. Immunoglobulin replacement for secondary immunodeficiency after B-cell targeted therapies in autoimmune rheumatic disease: Systematic literature review. Autoimmun Rev 2019;18:535-41. [PMID: 30844552 DOI: 10.1016/j.autrev.2019.03.010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
26 Roccatello D. "How I treat" autoimmune diseases: State of the art on the management of rare rheumatic diseases and ANCA-associated systemic idiopathic vasculitis. Autoimmun Rev 2017;16:995-8. [PMID: 28780080 DOI: 10.1016/j.autrev.2017.07.015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
27 Adawi M, Bragazzi NL, McGonagle D, Watad S, Mahroum N, Damiani G, Conic R, Bridgewood C, Mahagna H, Giacomelli L, Eggenhöffner R, Mahamid M, Pigatto PDM, Amital H, Watad A. Immunogenicity, safety and tolerability of anti-pneumococcal vaccination in systemic lupus erythematosus patients: An evidence-informed and PRISMA compliant systematic review and meta-analysis. Autoimmun Rev 2019;18:73-92. [PMID: 30408581 DOI: 10.1016/j.autrev.2018.08.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
28 Chen YX, Chen XN. Antineutrophil cytoplasmic antibodies-associated glomerulonephritis: From bench to bedside. Chronic Dis Transl Med 2018;4:187-91. [PMID: 30276365 DOI: 10.1016/j.cdtm.2018.05.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
29 Vivarelli M, Colucci M, Gargiulo A, Bettini C, Lo Russo A, Emma F. Belimumab for the treatment of children with frequently relapsing nephrotic syndrome: the BELNEPH study. Pediatr Nephrol 2021. [PMID: 34383126 DOI: 10.1007/s00467-021-05175-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Duarte I, Oliveira J, Outerelo C, Godinho I, Pereira M, Fernandes P, Jorge S, Gameiro J. Rituximab in glomerular diseases: a case series and narrative review. J Bras Nefrol 2021:S0101-28002021005081301. [PMID: 34874051 DOI: 10.1590/2175-8239-JBN-2021-0120] [Reference Citation Analysis]
31 Biotti D, Lerebours F, Bonneville F, Ciron J, Clanet M, Brassat D. Late-onset neutropenia and neurological relapse, during long-term rituximab therapy in myelin oligodendrocyte glycoprotein-antibody spectrum disorder. Mult Scler 2018;24:1645-7. [DOI: 10.1177/1352458518765677] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
32 Gauckler P, Shin JI, Alberici F, Audard V, Bruchfeld A, Busch M, Cheung CK, Crnogorac M, Delbarba E, Eller K, Faguer S, Galesic K, Griffin S, Hrušková Z, Jeyabalan A, Karras A, King C, Kohli HS, Maas R, Mayer G, Moiseev S, Muto M, Odler B, Pepper RJ, Quintana LF, Radhakrishnan J, Ramachandran R, Salama AD, Segelmark M, Tesař V, Wetzels J, Willcocks L, Windpessl M, Zand L, Zonozi R, Kronbichler A; RITERM study group. Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown? Autoimmun Rev 2020;19:102671. [PMID: 32942039 DOI: 10.1016/j.autrev.2020.102671] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]